Pharma BD Deal Intelligence
A steep discount buyback: MeiraGTx paid $25 million to reclaim bota-vec from Johnson & Johnson after the Phase 3 LUMEOS trial missed its primary visual-navigation endpoint, a fraction of the original deal's $130 million upfront and up to $415 million total.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →J&J gene therapy fails to improve visual navigation in late-stage rare eye disease trial. The phase 3 LUMEOS trial of bota-vec failed to demonstrate a…
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing. MeiraGTx has acquired botaretigene sparoparvovec (bota-vec), a gene therapy for…
Q1 2026 results: MeiraGTx PAID J&J a one-time $25M upfront cash consideration; J&J eligible for a one-time regulatory/commercial milestone tied to U.S.…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
In April 2026 MeiraGTx (Nasdaq: MGTX) entered into an asset purchase agreement with Johnson & Johnson (Janssen) to re-acquire all global rights to botaretigene sparoparvovec (bota-vec), an AAV5-RPGR gene therapy for X-linked retinitis pigmentosa (XLRP) that MeiraGTx had originally developed and out-licensed to Janssen. MeiraGTx paid a one-time $25 million upfront cash payment; J&J is eligible for a single regulatory-and-commercial milestone tied to U.S. approval and U.S. sales, plus a royalty on global net sales beginning mid-2029. (MeiraGTx's deal-announcement release described the royalty as 'high double-digit' while its Q1 2026 results characterized it as 'mid-teens' — the precise rate is undisclosed/contested.) The hand-back followed the Phase 3 LUMEOS trial missing its primary visual-navigation endpoint in 2025; MeiraGTx intends to file BLA/MAA in the U.S., EU and Japan on the strength of secondary endpoint and safety data, targeting a potential 2027 launch. Separately and concurrently, MeiraGTx priced an underwritten offering of 11,111,111 ordinary shares at $9.00, raising ~$100 million gross to fund the program (the financing is distinct from the $25M asset purchase price).
5K US cases/yr
X-linked retinitis pigmentosa is a rare inherited retinal dystrophy predominantly affecting males, caused most commonly by RPGR gene mutations (~75% of cases). Patients experience progressive rod-cone degeneration with childhood-onset night blindness, peripheral visual field constriction, and eventual legal blindness by the fourth decade. There is no approved disease-modifying therapy.
The XLRP gene therapy field is led by MeiraGTx's bota-vec (AAV5-RPGR, hand-back from J&J) and 4D Molecular Therapeutics' 4D-125 (intravitreal AAV-RPGR). Beacon Therapeutics' AGTC-501 (laruparetigene zovaparvovec) is in Phase 3. The phase 3 LUMEOS trial of bota-vec missed its primary endpoint on visual navigation, complicating regulatory positioning despite secondary efficacy signals.
MeiraGTx paid J&J a one-time $25M upfront to re-acquire all global rights to bota-vec; milestone on U.S. approval/sales plus royalty from mid-2029. Confirmed paid in MeiraGTx Q1 2026 results (8-K, May 14 2026).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MeiraGTx Holdings plc / Johnson & Johnson (Janssen Pharmaceuticals) (this deal) | 2026 | $25M | — |
| Johnson & Johnson / Abbott Medical Optics | 2003 | $4.3B | 70 |
| Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) | 2016 | $4.3B | 66 |
| Merck & Co. Inc. / EyeBio Ltd. | 2024 | $3.0B | 61 |
| Viatris / Oyster Point Pharma, Inc. | 2022 | $299M | 58 |
| Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. | 2026 | — | 51 |
| EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) | 2000 | $32M | 47 |
← Browse all deals · How we score deals
More: 2026 deals · Ophthalmology deals